Navigation Links
Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy
Date:4/3/2011

/a>

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive NHL, that the substitution of pixantrone for doxorubicin in the CHOP regimen may not produces complete remissions and long-term disease free survival in patients with relapsed or refractory, aggressive NHL who previously failed frontline CHOP therapy, that there may not be a correlation between CR/CRu's and progression free survival, that pixantrone may not show an overall improvement rate in survival for patients independent of factors known to influence survival, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials or the total number of patients enrolled, that CTI cannot predict whether PIX-R will serve as either a post-marketing commitment trial or as a pivotal trial, that CTI cannot predict the outcome of the formal dispute resolution process with the FDA, that the FDA may not make its decision on the appeal in the second quarter of 2011, that the FDA may request additional clinical trials, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDAs Office of New Drugs Meets With Cell Therapeutics on its Appeal on Pixantrone
2. Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma
3. European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
4. Cell Therapeutics Announces FDAs Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkins Lymphoma, February 10, 2010
5. Inability of Pixantrone to Form Toxic Iron Complexes Results in Significant Reduction in Cardiac Cell Toxicity Compared to Currently Marketed Anthracyclines
6. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
7. FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
8. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
9. Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options
10. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
11. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014 /PRNewswire-iReach/ -- Market ... Hydrochloride Industry, 2009-2019 is a professional and ... Oxybutynin Hydrochloride industry. The report firstly reviews ... its classification, application and manufacturing technology. The ... manufacturers of Oxybutynin Hydrochloride listing their product ...
(Date:9/19/2014)... 19, 2014 Research ... the addition of the "Global Gynecological ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... classified into wide categories based on their ... treatment of different gynecological conditions that affect ...
(Date:9/19/2014)... September 19, 2014 According ... Equipment (Cryotherapy, Heat, therapy, Hydrotherapy), Accessories (Posture Mirror, Exercise ... Advanced technologies - Global Forecast to 2019" published ... to reach $19,786.3 Million by 2019 from $14,240.0 ... from 2014 to 2019. Browse 74 ...
Breaking Medicine Technology:Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 2Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 3Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 4Oxybutynin Hydrochloride Industry 2014-2019 Chinese Forecasts & Analysis 5Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 2Global Gynecological Devices Market 2014-2018: Key Vendors are Bayer, Boston Scientific, CooperSurgical, Ethicon, Hologic, Medtronic, Olympus and Stryker 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 2Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 3Physiotherapy Equipment Market Worth $19,786.3 Million by 2019 4
(Date:9/20/2014)... (PRWEB) September 20, 2014 The first ... is now in its third week in the U.S. ... LLC reports. Court documents indicate that the week opened ... with testimony from a DePuy Orthopaedics vice president, who ... of the company’s Pinnacle hip replacement. According to Reuters, ...
(Date:9/20/2014)... (PRWEB) September 20, 2014 MarijuanaDoctors.com ... successful showing at the PAIN Week conference that ... Hotel and Casino in Las Vegas from September ... primarily attended PAIN Week in the hopes of ... a viable and legitimate tool to treat chronic ...
(Date:9/19/2014)... 20, 2014 Nearly 780 Risperdal lawsuits ... Pleas where a meeting took place to discuss the ... in the court’s mass tort program. Attorneys for ... past week at the Complex Litigation Center in Philadelphia’s ... pretrial proceedings. The Risperdal lawsuits filed against Johnson & ...
(Date:9/19/2014)... 19, 2014 “Copay coupons,” a drug ... brand drugs among patients with prescription drug coverage, may ... a new report from the Department of Health ... Federal anti-kickback laws prohibit suppliers from offering side-payments to ... federal government. , The report highlights that two recent ...
(Date:9/19/2014)... September 19, 2014 Unbound , an ... families in regions of the Philippines being affected by both ... than 1,060 families evacuated to the nearest public schools while ... heavy rain and gusty winds to portions of the northern ... flooding. Some homes filled with more than 10 feet of ...
Breaking Medicine News(10 mins):Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4Health News:MarijuanaDoctors.com Experiences Unprecedented Support and Growth at Pain Week 2014 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 2Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 3Health News:Risperdal Lawsuits Move Forward As Attorneys Meet To Discuss Litigation, Reports Wright & Schulte LLC 4Health News:PCMA: New OIG Report Cites Drug Manufacturer“Copay Coupon” Use in Medicare Part D 2Health News:Double Threat in Philippines Displaces Thousands of Unbound Families 2
... (BRONX, NY) The National Institute of Diabetes and ... of Health (NIH) has awarded Albert Einstein College of ... for the continuation of its Diabetes Research and Training ... supplemental grant for equipment and additional pilot and feasibility ...
... and a friend dares you to eat a raw crayfish ... a severe parasitic infection. Physicians at Washington University School of ... six people who had consumed raw crayfish from streams and rivers ... three have been diagnosed since last September; the latest in April. ...
... high-risk women opt for lumpectomy , TUESDAY, May 25 ... before surgery enhances their chances of being able to ... new research suggests. , The observation was based on ... United States. It focused on postmenopausal women who had ...
... suggest that bacteria residing in the the human intestinal ... developing colon cancer. Scientists from the University of Florida ... of the American Society for Microbiology in San Diego, ... are more frequently detected in subjects with polyps, early ...
... indicated higher, lower risk of disease, study finds , ... germs living in your gut could affect your risk ... signs of the existence of some germs "are more ... can develop into cancer, while other bacterial signatures are ...
... in French . Montreal, May 25, 2010 ... French and English, at local bookstores and pharmacies. Dr. Jean-Daniel ... Department of Ophthalmology, along with two colleagues from France, have ... Macular Degeneration (Annika Parance Publisher; 121 pages). Written to educate ...
Cached Medicine News:Health News:NIH awards $10M to Einstein for diabetes research 2Health News:NIH awards $10M to Einstein for diabetes research 3Health News:Dangerous lung worms found in people who eat raw crayfish 2Health News:Dangerous lung worms found in people who eat raw crayfish 3Health News:Dangerous lung worms found in people who eat raw crayfish 4Health News:Breast Cancer Study Offers New Hope 2Health News:Book on vision loss: AMD affects 1 million Canadians 2
... catheter is designed to remove thrombus ... saline jets travel backwards at half ... a low pressure zone causing a ... the catheter where it is fragmented ...
... Electroanatomical Mapping System combines the legendary accuracy ... ease of Windows* software. It integrates ... new tools that enhance your clinical capabilities ... into the future of EP. The ...
... are meeting the clinical needs of ... anesthesiologists. And, they are of the ... Medtronic.,Effective pacing with the adjustment of ... quick battery changes. Both the ...
... The Kantrowitz CardioVad is a unique left ventricular ... more effectively. It is being used in a ... heart failure as part of an FDA-approved Feasibility ... and disconnect the external power source for minutes ...
Medicine Products: